{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:29:32Z","timestamp":1790994572976,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Perinatology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.semperi.2020.151222","type":"journal-article","created":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T21:46:18Z","timestamp":1579902378000},"page":"151222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Pharmacogenomics in pregnancy"],"prefix":"10.1016","volume":"44","author":[{"given":"Hannah K.","family":"Betcher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Alfred L.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.semperi.2020.151222_bib0001","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/sj.clpt.6100087","article-title":"The pharmacogenetics research network: from SNP discovery to clinical drug response","volume":"81","author":"Giacomini","year":"2007","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.semperi.2020.151222_bib0002","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/clpt.2013.203","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-alpha-based regimens","volume":"95","author":"Muir","year":"2014","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.semperi.2020.151222_bib0003","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/clpt.2013.254","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update","volume":"95","author":"Crews","year":"2014","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.semperi.2020.151222_bib0004","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/clpt.2014.38","article-title":"Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update","volume":"95","author":"Martin","year":"2014","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.semperi.2020.151222_bib0005","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/clpt.2014.97","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype","volume":"96","author":"Relling","year":"2014","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.semperi.2020.151222_bib0006","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/clpt.2014.159","article-title":"Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing","volume":"96","author":"Caudle","year":"2014","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.semperi.2020.151222_bib0007","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/clpt.2014.125","article-title":"The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update","volume":"96","author":"Ramsey","year":"2014","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.semperi.2020.151222_bib0008","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2174\/1389200215666140130124910","article-title":"Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process","volume":"15","author":"Caudle","year":"2014","journal-title":"Curr Drug Metab"},{"issue":"4","key":"10.1016\/j.semperi.2020.151222_bib0009","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/clpt.2013.4","article-title":"Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update","volume":"93","author":"Relling","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.semperi.2020.151222_bib0010","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/clpt.2013.105","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update","volume":"94","author":"Scott","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.semperi.2020.151222_bib0011","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/clpt.2013.103","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing","volume":"94","author":"Leckband","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.semperi.2020.151222_bib0012","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/clpt.2011.287","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype","volume":"91","author":"Crews","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.semperi.2020.151222_bib0013","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/clpt.2012.57","article-title":"The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy","volume":"92","author":"Wilke","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.semperi.2020.151222_bib0014","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/clpt.2011.185","article-title":"Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing","volume":"90","author":"Johnson","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.semperi.2020.151222_bib0015","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/ajmg.c.31396","article-title":"Implementation of pharmacogenetics: the University of Maryland Personalized Anti-platelet Pharmacogenetics Program","volume":"166C","author":"Shuldiner","year":"2014","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"1","key":"10.1016\/j.semperi.2020.151222_bib0016","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ajmg.c.31390","article-title":"Clinical pharmacogenetics implementation: approaches, successes, and challenges","volume":"166C","author":"Weitzel","year":"2014","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"1","key":"10.1016\/j.semperi.2020.151222_bib0017","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/ajmg.c.31391","article-title":"PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics","volume":"166C","author":"Hoffman","year":"2014","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"1","key":"10.1016\/j.semperi.2020.151222_bib0018","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/clpt.2011.371","article-title":"Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project","volume":"92","author":"Pulley","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.semperi.2020.151222_bib0019","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/clpt.2012.117","article-title":"The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics","volume":"92","author":"O'Donnell","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.semperi.2020.151222_bib0020","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ajmg.c.31385","article-title":"Adoption of a clinical pharmacogenomics implementation program during outpatient care\u2013initial results of the University of Chicago \"1,200 Patients Project\"","volume":"166C","author":"O'Donnell","year":"2014","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"6","key":"10.1016\/j.semperi.2020.151222_bib0021","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1161\/CIRCOUTCOMES.113.000321","article-title":"Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention","volume":"6","author":"Desai","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"9","key":"10.1016\/j.semperi.2020.151222_bib0022","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1124\/dmd.109.026609","article-title":"Up-regulation of UDP-glucuronosyltransferase (UGT) 1A4 by 17beta-estradiol: a potential mechanism of increased lamotrigine elimination in pregnancy","volume":"37","author":"Chen","year":"2009","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.semperi.2020.151222_bib0023","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/acn3.29","article-title":"Model-Based Lamotrigine Clearance Changes during Pregnancy: Clinical Implication","volume":"1","author":"Polepally","year":"2014","journal-title":"Ann Clin Transl Neurol"},{"issue":"9","key":"10.1016\/j.semperi.2020.151222_bib0024","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1111\/j.1528-1167.2005.10105.x","article-title":"Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations","volume":"46","author":"Reimers","year":"2005","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.semperi.2020.151222_bib0025","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/00498250701744633","article-title":"Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination","volume":"38","author":"Jeong","year":"2008","journal-title":"Xenobiotica"},{"issue":"5","key":"10.1016\/j.semperi.2020.151222_bib0026","first-page":"515","article-title":"Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs","volume":"24","author":"Shimada","year":"1996","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.semperi.2020.151222_bib0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10408449209145319","article-title":"The human hepatic cytochromes P450 involved in drug metabolism","volume":"22","author":"Wrighton","year":"1992","journal-title":"Crit Rev Toxicol"},{"issue":"3","key":"10.1016\/j.semperi.2020.151222_bib0028","first-page":"174","article-title":"Oral nifedipine pharmacokinetics in pregnancy-induced hypertension","volume":"12","author":"Prevost","year":"1992","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.1016\/j.semperi.2020.151222_bib0029","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.tips.2004.02.007","article-title":"Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future","volume":"25","author":"Ingelman-Sundberg","year":"2004","journal-title":"Trends Pharmacol Sci"},{"issue":"4","key":"10.1016\/j.semperi.2020.151222_bib0030","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0009-9236(97)90118-1","article-title":"Induction of CYP2D6 in pregnancy","volume":"62","author":"Wadelius","year":"1997","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.semperi.2020.151222_bib0031","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1634\/theoncologist.11-2-126","article-title":"Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications","volume":"11","author":"Bernard","year":"2006","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.semperi.2020.151222_bib0032","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ajog.2004.08.030","article-title":"National Institute for Child H, Human Development Network of Maternal-Fetal-Medicine U. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy","volume":"192","author":"Tracy","year":"2005","journal-title":"Am J Obstet Gynecol"},{"issue":"10","key":"10.1016\/j.semperi.2020.151222_bib0033","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2165\/11318050-000000000-00000","article-title":"Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy","volume":"48","author":"Ververs","year":"2009","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.semperi.2020.151222_bib0034","doi-asserted-by":"crossref","first-page":"652","DOI":"10.4088\/JCP.v69n0419","article-title":"Changes in antidepressant metabolism and dosing across pregnancy and early postpartum","volume":"69","author":"Sit","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"10.1016\/j.semperi.2020.151222_bib0035","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2165\/00003088-200544100-00001","article-title":"Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach","volume":"44","author":"Anderson","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.semperi.2020.151222_bib0036","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1159\/000457332","article-title":"Pharmacokinetics of caffeine during and after pregnancy","volume":"6","author":"Brazier","year":"1983","journal-title":"Dev Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.semperi.2020.151222_bib0037","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00228-003-0651-x","article-title":"Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil","volume":"59","author":"McGready","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.semperi.2020.151222_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2011.02.029","article-title":"Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008","volume":"205","author":"Mitchell","year":"2011","journal-title":"Am J Obstet Gynecol"},{"issue":"9","key":"10.1016\/j.semperi.2020.151222_bib0039","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/pds.3495","article-title":"Medications in the first trimester of pregnancy: most common exposures and critical gaps in understanding fetal risk","volume":"22","author":"Thorpe","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9536","key":"10.1016\/j.semperi.2020.151222_bib0040","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S0140-6736(06)69255-6","article-title":"Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother","volume":"368","author":"Koren","year":"2006","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.semperi.2020.151222_bib0041","first-page":"1077","article-title":"Guidelines for maternal codeine use during breastfeeding","volume":"55","author":"Madadi","year":"2009","journal-title":"Can Fam Physician"},{"issue":"1521","key":"10.1016\/j.semperi.2020.151222_bib0042","first-page":"86","article-title":"FDA warns against use of codeine and tramadol in children and breastfeeding women","volume":"59","year":"2017","journal-title":"Med Lett Drugs Ther"},{"issue":"3","key":"10.1016\/j.semperi.2020.151222_bib0043","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/00000542-200503000-00011","article-title":"The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis?","volume":"102","author":"Candiotti","year":"2005","journal-title":"Anesthesiology"},{"issue":"2","key":"10.1016\/j.semperi.2020.151222_bib0044","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/cpt.598","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron","volume":"102","author":"Bell","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.semperi.2020.151222_bib0045","unstructured":"Highlights of Prescribing Information: Zofran (ondansetron hydrochloride) injection, for intravenous or intramuscular use. In: GalxoSmithKline, ed. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/020007s047lbl.pdf. Reference ID: 4066238 ed. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/020007s047lbl.pdf: GlaxoSmithKline; 2017."},{"key":"10.1016\/j.semperi.2020.151222_bib0046","unstructured":"Highlights of Prescribing Information: Reglan (metoclopramide) tablets, for oral use. In: ANI Pharmaceuticals I, ed. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/017854s062lbl.pdf. Vol Reference ID: 4145755. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/017854s062lbl.pdf2017."},{"issue":"3","key":"10.1016\/j.semperi.2020.151222_bib0047","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/BF00271365","article-title":"Plasma concentration-effect relationship of metoprolol during and after pregnancy","volume":"44","author":"Hogstedt","year":"1993","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.semperi.2020.151222_bib0048","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/clpt.1985.114","article-title":"Pregnancy-induced increase in metoprolol metabolism","volume":"37","author":"Hogstedt","year":"1985","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.semperi.2020.151222_bib0049","unstructured":"LP A. Highlights of Prescribing Information: Toprol-XL (metoprolol succinate). In: LP A, ed. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/019962s044lbl.pdf. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/019962s044lbl.pdf2012, 2013:15."},{"issue":"2","key":"10.1016\/j.semperi.2020.151222_bib0050","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cpt.147","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors","volume":"98","author":"Hicks","year":"2015","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.semperi.2020.151222_bib0051","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0009-9236(02)17634-X","article-title":"Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation","volume":"73","author":"Heikkinen","year":"2003","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.semperi.2020.151222_bib0052","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00008571-199902000-00008","article-title":"The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine","volume":"9","author":"Fjordside","year":"1999","journal-title":"Pharmacogenetics"},{"issue":"3","key":"10.1016\/j.semperi.2020.151222_bib0053","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/00004714-200106000-00013","article-title":"Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers","volume":"21","author":"Eap","year":"2001","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.semperi.2020.151222_bib0054","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/cpt.597","article-title":"Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update","volume":"102","author":"Hicks","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.semperi.2020.151222_bib0055","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/cpt.375","article-title":"Rationale and design for an investigation to optimize selective serotonin reuptake inhibitor treatment for pregnant women with depression","volume":"100","author":"Avram","year":"2016","journal-title":"Clin Pharmacol Ther"}],"container-title":["Seminars in Perinatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146000520300033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146000520300033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T17:47:53Z","timestamp":1614102473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146000520300033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0146000520300033"],"URL":"https:\/\/doi.org\/10.1016\/j.semperi.2020.151222","relation":{},"ISSN":["0146-0005"],"issn-type":[{"value":"0146-0005","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacogenomics in pregnancy","name":"articletitle","label":"Article Title"},{"value":"Seminars in Perinatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semperi.2020.151222","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"151222"}}